Can I take injection FCM (Ferric Carboxymaltose) during the 3rd day of menstruation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can You Take FCM Injection on Day 3 of Menstruation?

Yes, you can safely receive ferric carboxymaltose (FCM) injection on the 3rd day of your menstrual period—there are no contraindications to administering intravenous iron during active menstruation.

Safety During Menstruation

  • Menstruation is not a contraindication to FCM administration, as the injection does not interact with or exacerbate menstrual bleeding 1.

  • FCM is specifically indicated for treating iron deficiency anemia associated with heavy uterine bleeding, demonstrating its safety profile in patients with ongoing menstrual blood loss 1.

  • The mechanism of FCM involves slow release of elemental iron from a macromolecular complex, which does not affect coagulation or bleeding parameters 1.

Clinical Context for FCM Use

FCM is particularly appropriate for women with heavy menstrual bleeding who develop iron deficiency anemia, as this represents one of the primary indications for the medication 1.

Administration Guidelines

  • FCM should be diluted in 100 mL of normal saline and infused over 20-30 minutes 1.

  • The infusion should start slowly with observation for several minutes to monitor for acute infusion reactions 1.

  • In the United States, FCM is typically given as 750 mg doses, with two doses administered 1 week apart 1.

  • Throughout Europe and Asia, FCM is routinely administered as a single 1000 mg infusion 1.

Important Considerations

Hypophosphatemia Risk

  • FCM is associated with treatment-emergent hypophosphatemia, particularly with repeat infusions 1, 2.

  • This risk is significantly higher with FCM compared to other formulations like ferric derisomaltose (FDI) 2.

  • If you require repeated iron infusions over time, alternative formulations should be considered to avoid severe hypophosphatemia and potential osteomalacia 2.

Monitoring After Administration

  • Laboratory evaluation should include a complete blood count and iron parameters (ferritin, transferrin saturation) 4-8 weeks after the last infusion 1.

  • Baseline serum phosphate concentrations should be checked before administration, especially if repeat dosing is anticipated 2.

Common Pitfall to Avoid

Do not delay necessary iron replacement therapy due to concerns about menstruation—active menstrual bleeding is not a contraindication to FCM administration, and delaying treatment perpetuates the iron deficiency that may be contributing to heavy bleeding 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.